Background: is a multifunctional signal microRNA that participates in a variety of cardiovascular diseases and is involved in physiological and pathological processes in different cell types. Objective: The objective of this article is to examine the effect of miR-155 on angiotensin II (Ang II)-induced primary mice vascular smooth muscle cell (VSMC) proliferation. Methods: Primary cultured VSMCs from the aorta of C57/BL6 mice were incubated with Ang II and miR-155. Cells were counted using CCK-8 and EdU, and flow cytometric analysis of cell cycle progression was performed. Angiotensin II 1 type receptor (AT1R) gene and protein expression were measured by real-time polymerase chain reaction and Western blotting. Results: 1) Ang II increased the viability of VSMCs in a dose-and time-dependent manner. 2) miR-155 opposed the Ang II-induced increase in VSMC viability. 3) miR-155 inhibited Ang II-induced proliferation of VSMCs. 4) miR-155 increased the number of VSMCs in the G1 phase compared to G2 and M cell cycle phases. 5) miR-155 decreased ATR1 gene and protein expression. Conclusion: miR-155 downregulation of Ang II-induced VSMC viability identifies it as an important regulator of cell proliferation.
Introduction
Vascular smooth muscle cell (VSMC) proliferation is a common pathological basis for atherosclerosis (AS), hypertension and vascular restenosis. Various cardiovascular disease risk factors lead to damage to the blood vessel wall and cellular infiltration. In particular, a variety of cytokines and growth factors activate their corresponding receptors in VSMCs, activating cytoplasmic signal transduction pathways and increasing gene expression, culminating in the proliferation of VSMCs 1 and finally leading to the development of various diseases.
Angiotensin II (Ang II) is the principal active peptide in the renin-angiotensin system. Physiologically, Ang II has a major impact on the cardiac and vascular function through regulation of systemic hemodynamics and blood volume. However, Ang II is also widely recognized as a critical regulator of VSMC proliferation and migration, which a recent study has demonstrated are important mechanisms in cardiovascular remodeling, 2 and which confirmed that the renin-angiotensin system is involved in AS pathogenesis. Ang II induces an inflammatory response by promoting apoptosis, low-density lipoprotein oxidation and transfer, and the production of oxygen radicals, which together affect fibrinolytic functions involved in the formation and development of AS. The biological effects of Ang II are mediated mainly by the Ang II type 1 receptor (AT1R), and together they constitute one of the most important pathways in VSMC proliferation. 3 For example, Ang II and AT1R are expressed at higher levels in AS and the expression of AT1R expression in the lining of the artery correlates with the severity of this disease. 4 microRNAs (miRNAs) are expressed in, and play many important biological functions in, the cardiovascular system, and deregulation of miRNAs is believed to be involved in a variety of diseases, including cancer and cardiovascular disease. 5 The best known function of miRNAs is the repression of translation by binding to the 3'UTR of mRNAs. A recent study 6 has shown that the AT1R 3'UTR is a target of miR-155 in human umbilical vein endothelial cells (HUVECs), and that miR-155 is highly expressed in VSMCs. It remains unclear, however, whether miR-155 is involved in Ang II-induced VSMC proliferation. The aim of the present study, therefore, was to explore the effects of miR-155 on the Ang II-induced proliferation of primary cultured mouse aortic VSMCs, and also to investigate the role of the AT1R pathway in this process.
Materials and methods

Materials
Ang II and propodium iodide (PI) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Dulbecco's modified Eagle's medium (DMEM), fetal bovine serum (FBS) and Opti-MEM were purchased from HyClone (HyClone, Logan, CT, USA). The miR-155 mimic, inhibitor and negative control were purchased from GenePharma (Shanghai, China). Cell counting kit-8 (CCK-8) reagent for cell proliferation was purchased from Dojindo (Kumamoto, Japan). The 5-ethynyl-2'-deoxyuridine (EdU) kit used for the proliferation of VSMCs came from Ribobio (Guangzhou, China). Trizol reagent for RNA isolation and Lip2000 reagent for transfection were from Invitrogen (Carlsbad, CA, USA). The one-step reverse transcription-polymerase chain reaction (RT-PCR) kit and the SYBR Green II Real-time PCR Kit were purchased from TaKaRa (Dalian, China). The rabbit monoclonal antibody to AT1R was purchased from Abcam (Cambridge, MA, USA), and the mouse monoclonal antibody to β-actin was obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Cell culture
Aortic smooth muscle cells were isolated from C57/BL6 mice (8 weeks old). Briefly, the aorta was carefully dissected free from surrounding tissue, rinsed in phosphatebuffered saline (PBS) and cut into about 1 mm 3 size, then placed in flasks. VSMCs were cultured in DMEM supplemented with 10% FBS, penicillin (100 U/ml) and streptomycin (100 µg/ml) at 37°C in a humidified atmosphere in 5% CO 2 . Cells were selected between passages 4 and 10. Prior to stimulation, cells first underwent mitotic quiescence by starvation in DMEM for 24 hours.
miRNA transfection
Prior to large-scale transfection, conditions were optimized to 1 × 10 5 cells cultured in six-or 96-well plates in Opti-MEM serum-reduced medium, and allowed to attach overnight. The Lipofectamine 2000 procedure was carried out according to the manufacturer's recommendation. The miRNA-155 and negative control oligonucleotde containing a 6-carboxy-fluorescein (FAM) moiety at the 5'end were diluted in the medium to a final concentration of 10 nM. Cells were incubated with miRNA-155 mimics, inhibitors and negative control (NC) for 24 hours using the fast transfection protocol as recommended by the manufacturer. All transfections were carried out in triplicate.
Cell viability assay
A CCK-8 assay was used to measure cell proliferation and viability. VSMCs were resuspended in 200 µl of cell culture medium and seeded in 96-well microtiter plates at 2 × 10 4 cells/ml, incubated overnight to allow for cell attachment, after which they were transfected with miR-155 mimic, inhibitor or negative control and incubated with Ang II (10 -6 M). Ten µl of CCK-8 reagent were added to each well one hour before the end of incubation. The optical density value (OD) of each sample was measured at a wavelength of 450 nm on a microplate reader (Molecular Devices, Palo Alto, CA). The result of cell viability measurement is expressed as the absorbance at OD450. Control cells were treated in the same way, and the value of absorbance was defined as 100% survival.
Immunocytochemistry
Logarithmic growth phase cells were seeded in 24-well plates and incubated with serum-free DMEM for 24 hours. Cells were transfected for 24 hours and stimulated with Ang II for 48 hours. In brief, EdU solution was added to cell culture medium to a final concentration of 1:1000, then incubated for two hours. Cell fixative (containing 4% paraformaldehyde in PBS) was added before incubation at room temperature for 30 minutes to fix the cells. 100 µl 1 × Apollo staining reaction liquid was added to each well at room temperature in the dark, the Shaker incubation 30 minutes to Apollo staining. Finally, DNA staining was carried out. Samples were stored in the dark at 4°C prior to laser scanning confocal microscopy. Experiments were repeated three times.
Flow cytometry
VSMCs were plated in six-well plates and transfected with miRNA (20 µmol/l) or miRNA-negative controls (20 µmol/l) for 24 hours. After stimulation with Ang II, the cells were digested with trypsin and fixed in 70% ice-cold ethanol overnight at -20°C. Cells were washed again and resuspended in PBS containing RNase and stained with PI for 30 minutes at room temperature. The intracellular PI fluorescence intensity of each population of 1 × 10 6 cells was measured in each sample using a flow cytometer (BD Biosciences).
RT-PCR
Total RNA, including miRNA, was extracted from the cells using Trizol reagent according to the manufacturer's protocol. The concentration and purity of the RNA samples were quantified using a spectrophotometer. The samples were used only if the ratio of the absorbance at 260 and 280 nm (A260/280) was between 1.8 and 2.0, and samples were diluted with diethylpyrocarbonate (DEPC)-treated water. cDNA was synthesized from total RNA using stem-loop RT primers according to the MicroRNA Assay protocol. Total RNA was isolated with Trizol reagent according to the manufacturer's protocol. In brief, miRNAs were reversetranscribed to cDNA using ReverTraAce reverse transcriptase. AT1R primers were as follows: forward primer (5'-AACAGCTTGGTGGTGATCGTC-3') and reverse primer (5'-CATAGCGGTATAGACAGCCCA-3'). The housekeeping gene β-actin was amplified as an internal control for normalization using the forward primer (5'-CATCCGTAAAGACCTCTATGCCAAC-3') and the reverse primer (5'-ATGGAGCCACCGATCCACA-3'). The cycling program was: 95°C for 30 seconds, 95°C for 15 seconds, 60°C for 20 seconds, 72°C for 10 seconds, 72°C for 90 seconds, 95°C for 30 seconds, 55°C for 30 seconds and 55°C for 15 seconds. The mRNA was measured by SYBR Green II fluorescence, and the SYBR RT-PCR kit was an iQ5 Real-Time PCR Detection System (Bio-Rad, Hercules, CA, USA), respectively. The relative expression level of miRNAs was normalized to the internal control U6 using the ∆∆Ct value method. AT1R and β-actin, an endogenous control gene, were assayed simultaneously. The results were analyzed using BioRad iQ TM 5 software.
Protein extraction and Western blotting
Cells were washed three times with ice-cold PBS. Treated VSMCs were lysed in 100 µl radioimmunoprecipitation assay (RIPA) buffer (50 mmol/l Tris pH 7.4, 150 mmol/l NaCl, 1% TritonX -100, 1% sodium pyrophosphate, 1 mmol/l ethylenediamine tetra-acetic acid (EDTA), 1% Na3VO4, 0.5 µg/ml leupeptin, and 1 mmol/l phenylmethyl-sulfony1 fluoride (PMSF)). The protein concentration was determined using the bicinchoninic acid (BCA) method. Equal amounts of proteins were resolved by 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and then transferred to nitrocellulose membrane. Nitrocellulose membranes were blocked with 5% nonfat dry milk in Tris-buffered saline (TBS) buffer with Tween 20 for one hour at room temperature. Membranes were then incubated overnight with primary rabbit antibody against AT1R (1:500) at 4°C. Membranes were washed three times in TBS with 0.5% Tween 20 for 10 minutes each before incubation with fluorescent-labeled secondary anti-mouse antibody (1:5000) for 60 minutes. The results of Western blotting were quantified using the Odyssey Infrared Imaging System (LI-COR Biosciences, Lincoln, NE, USA). Fluorescent signals were quantified using Odyssey 2.0 software.
Statistical analysis
All data are reported as mean ± S.E.M. GraphPad Prism 5.0 software was used for statistical analysis. Groups of data were compared with analysis of variance (ANOVA) followed by Tukey's multiple comparison tests. A p value less than 0.05 was considered significant.
Results
Ang II increases proliferation of VSMCs
To determine whether Ang II regulated the proliferation of VSMCs, we used the CCK-8 assay to monitor cell viability. Cells were treated with Ang II at the concentrations indicated (0, 10 -8 ,10 -7 ,10 -6 ,10 -5 M) for 48 hours or treated with 10 -6 M Ang II for the time indicated (0, 6, 12, 24, 48 hours). These data demonstrated that Ang II increased the viability of VSMCs in a dose-and time-dependent manner (Figure  1 
miR-155 overexpression decreases Ang IIinduced VSMC viability
We next used a CCK-8 to assay examine whether miR-155 influences Ang II regulation of primary cultured VSMC viability. Firstly, miR-155 mimic, inhibitor and negative control were transfected into VMSCs, then the cells were stimulated with Ang II at the concentrations indicated (0, 10 -8 , 10 -7 , 10 -6 , 10 -5 M) for 48 hours or treated with 10 -6 M Ang II for the time indicated (0, 6, 12, 24, 48 hours). As shown in Figure 2 (a) and (b), compared to VSMCs transfected with Ang II and miR-155 negative control + Ang II, VSMCs transfected with miR-155 mimic + Ang II had significantly decreased proliferation. Based on these results we concluded that miR-155 overexpression inhibited Ang II-induced VSMC viability.
miR-155 overexpression inhibits Ang IIinduced proliferation of VSMCs
We next determined the effect of miR-155 on Ang II-induced VSMC proliferation. After transfection with miR-155 mimic, miR-155 negative control or miR-155 mimic plus inhibitor for 24 hours, cells were stimulated with 10 -6 M Ang II for an additional 48 hours prior to EdU assay. EdU-stained photomicrographs and corresponding photomicrographs of total cells are shown in Figure 3 (a). The proportion of cells with EdU-positive nuclei is shown in Figure 3 
miR-155 overexpression induces G1-phase arrest in Ang II-induced proliferating VSMCs
To evaluate the effect of miR-155 on DNA synthesis and cell growth, we used a flow cytometer to analyze the cell cycle status of VSMCs induced by Ang II (10 -6 M). Ang II treatment alone led to cellular migration into the S phase with a concomitant decrease of cells in the G0/G1 phase. However, compared with the Ang II control group, miR-155 diminished the Ang II-stimulated cell cycle progression into S phase and increased accumulation in G1 phase. These results indicated that miR-155 induces G1 cell cycle arrest in VSMCs, and significantly reduces the percentage of cells in the S and G2/M phases (Figure 4(a) and (b) ).
miR-155 overexpression decreases expression of AT1R mRNA and protein in VSMCs
AT1R mRNA and miR-155mRNA expression on the VSMCs were not affected by Ang II stimulation (see Supplementary material). To determine whether AT1R was involved in miR-155 inhibition of VSMC proliferation, we used real time RT-PCR and Western blotting to examine AT1R mRNA and protein status in miR-155-treated VSMCs. Expression of AT1R mRNA was significantly reduced in the miR-155 group compared with the control group (p < 0.01) and in the miR-155 group compared with the inhibitor group (p < 0.05) ( Figure 5(a) ). Expression of AT1R protein was reduced significantly in the miR-155treated group compared with the control group and the inhibitor group (p < 0.05) (Figure 5(b) and (c) ). These observations indicated that miR-155 downregulates the expression of AT1R in VSMCs.
Discussion
AS has been established as a chronic inflammatory disease in blood vessel walls and is the most frequent cause of death and morbidity in industrialized countries. [7] [8] [9] [10] VSMCs are major components of the vascular wall, and in advanced AS, they play a key role in fibrous cap formation and plaque stability. 11 Increased proliferation and migration of VSMCs from the media to the intima of vessels is an important pathological characteristic of AS. In the past few years, research has identified Ang II as an important factor in cardiovascular remodeling, as well as in the development of atherosclerosis, hypertension and restenosis. 12, 13 Moreover, it has been recognized as a critical regulator of VSMC proliferation and migration. 12, 13 Ang II has growth factor and cytokine-like properties and, during the development of AS, promotes VSMC migration, proliferation, apoptosis and phenotype translation, as well as the secretion and expression of many kinds of pro-inflammatory cytokines, growth factors and extracellular matrix proteins. Therefore, Ang II and VSMCs have important pathophysiological roles in the formation and development of AS.
Ang II is the final effector molecule of the reninangiotensin system. While the biological effects of Ang II are mediated by AT1R and the Ang II type 2 receptor (AT2R), Diep et al. 14 showed that VSMC proliferation is mediated mainly by AT1R, rather than AT2R. Other studies in macrophages have shown that AT1R antagonists inhibit the effect of Ang II, but AT2R antagonists do not. 15 The three clinical trials referred to above also demonstrated that selective AT1R antagonists can prevent atherogenesis. [16] [17] [18] miRNAs are recently discovered signaling molecules, some of which are closely related to inflammation. 19 miR-155 was an miRNA molecule, which was possibly involved in the occurrence of AS disease. Our study is the first to show that miR-155, an miRNA previously suggested to be involved in the etiology of AS, inhibits VSMC proliferation and decreases AT1R expression in mouse VSMCs. miRNAs are a highly conserved class of small, noncoding, double-stranded RNA molecules of about 22 nucleotides in length, and they play a major role in the post-transcriptional regulation of gene expression. By repressing target gene expression via translational inhibition or mRNA degradation, they take part in many physiological cellular processes, including cell proliferation, differentiation and apoptosis. 20, 21 Various miRNAs have been found to be associated with VSMC proliferation. For example, miR-221 and miR-222 have been shown to be novel regulators of VSMC proliferation and neointimal hyperplasia. 22 miR-145 is widely expressed in human atherosclerotic lesions. miR-145 expression is significantly modulated in human AS plaques from hypertensive patients. 23 Cordes et al. found that miR-145 can direct smooth muscle fate and that miR-145 and miR-143 function to regulate the quiescent vs proliferative phenotype of smooth muscle cells. 24 Moreover, Yu et al. identified let-7d as a potential regulator of VSMC proliferation via a Kirsten rat sarcoma viral oncogene homolog (KRAS)-related mechanism, 25 and Sun et al. demonstrated that miR-146a has an important role in promoting VSMC proliferation in vitro and vascular neointimal hyperplasia in vivo. 26 miR-155 is a multifunctional signal miRNA that has been reported to play a critical role in various physiological and pathological processes such as immunity, inflammation, cancer and cardiovascular disease. 27 miR-155 decreases proliferation and migration of human extravillous trophoblast-derived HTR-8/SVneo cells via downregulation of the cyclin D1 pathway. 28 Furthermore, increased miR-155 expression correlates with p27 kip1 accumulation in dendritic cells via a mechanism involving the Kip1 ubiquitination-promoting complex1 (KPC1), demonstrating the regulatory role of the miR-155-KPC1-p27 kip1 pathway in dendritic cell apoptosis. 29 miR-155 has been shown to be highly expressed in HUVECs and VSMCs, and AT1R has been shown to be a target of miR-155. By targeting AT1R, miR-155 decreases HUVEC migration in response to Ang II. 30 Collectively, these studies indicate that miR-155 is downregulated in many pathophysiological processes, and our study extends these observations by showing that miR-155 plays an important role in regulating the proliferation of Ang II-induced VSMCs.
In summary, we found that miR-155 significantly downregulated Ang II-induced proliferation of mouse VSMCs, an effect that was reversed by inhibition of miR-155. AT1R was identified as a functional target in the effect of miR-155 on mouse VSMCs: miR-155 transfection resulted in a decrease of AT1R expression and an inhibition of Ang II-induced VSMC proliferation. Our results indicate that miR-155 may be a potential therapeutic target of vasculoproliferative and vascular remodeling diseases, although elucidating the specific downstream targets of AT1R in this context will require further research. 
